Extrawell Pharmaceutical Holdings (HKSE:00858) COGS-to-Revenue : 0.52 (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings COGS-to-Revenue?

Extrawell Pharmaceutical Holdings's Cost of Goods Sold for the six months ended in Mar. 2024 was HK$15.07 Mil. Its Revenue for the six months ended in Mar. 2024 was HK$28.96 Mil.

Extrawell Pharmaceutical Holdings's COGS to Revenue for the six months ended in Mar. 2024 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Extrawell Pharmaceutical Holdings's Gross Margin % for the six months ended in Mar. 2024 was 47.96%.

Extrawell Pharmaceutical Holdings COGS-to-Revenue Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings COGS-to-Revenue Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

Get a 7-Day Free Trial

0.45

0.46

0.49

0.57

0.51

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.55	0.60	0.54	0.51	0.52

Extrawell Pharmaceutical Holdings COGS-to-Revenue Calculation

Extrawell Pharmaceutical Holdings's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	30.319	/	59.098
	=	0.51

Extrawell Pharmaceutical Holdings's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	15.069	/	28.957
	=	0.52

Extrawell Pharmaceutical Holdings (HKSE:00858) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Extrawell Pharmaceutical Holdings's Gross Margin % for the six months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	15.069 / 28.957
	=	47.96 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Extrawell Pharmaceutical Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Extrawell Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings Headlines

No Headlines